

A next-generation oral defence in Antibacterial therapy

FARORICHTM-300 ER

Tablets

Faropenem 300 mg ER

- Similar Spectrum to IV Penems (Meropenem, Imipenem)
- Alternative for quinolones & macrolides resistant bacteria
- Efficacy is unaffected by β -lactamase production (equal MIC₉₀ for positive and negative isolates)
- Step-down oral option to reduce IV antibiotic need
- Well tolerated by GI tract

Greater activity compared to other Antimicrobials

Pathogen	MIC ₉₀ (mg/L)		
	Faropenem	Cefuroxime	Co-amoxiclav
Streptococcus pneumoniae	0.25	4	1
MSSA	0.12	2	0.5
MRSA	2	>128	16
Haemophilus influenzae	1	2	2
Moraxella catarrhalis	0.5	2	0.25

Adv in Phar & Clin Trials 2023, 8(2): 000216. International Journal of Infectious Diseases 132 (2023) 99–107

- Acute bacterial sinusitis
- Community-acquired pneumonia
- Acute exacerbation of chronic bronchitis
- Uncomplicated skin infection

- 92.6% Cure rates in acute URTI & UTI
- Excellent synergy with Rifampicin for pulmonary tuberculosis (88%)

NEXT
Generation *Protection*

* >2 months for TB



Dose : One tab BID for 7-10 days*

The Only **Oral Penem**